GB9305735D0 - Novel agent for controlling cell activity - Google Patents

Novel agent for controlling cell activity

Info

Publication number
GB9305735D0
GB9305735D0 GB939305735A GB9305735A GB9305735D0 GB 9305735 D0 GB9305735 D0 GB 9305735D0 GB 939305735 A GB939305735 A GB 939305735A GB 9305735 A GB9305735 A GB 9305735A GB 9305735 D0 GB9305735 D0 GB 9305735D0
Authority
GB
United Kingdom
Prior art keywords
domain
agent
cell
cell activity
endosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB939305735A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB939305735A priority Critical patent/GB9305735D0/en
Publication of GB9305735D0 publication Critical patent/GB9305735D0/en
Priority to PL94310698A priority patent/PL178895B1/pl
Priority to AU62175/94A priority patent/AU671203C/en
Priority to AT94909262T priority patent/ATE228856T1/de
Priority to FI954390A priority patent/FI954390L/fi
Priority to PT94909262T priority patent/PT689459E/pt
Priority to BR9406232A priority patent/BR9406232A/pt
Priority to CA002158647A priority patent/CA2158647A1/en
Priority to HU9502673A priority patent/HU217220B/hu
Priority to SK1155-95A priority patent/SK115595A3/sk
Priority to JP52080694A priority patent/JP4300265B2/ja
Priority to EP94909262A priority patent/EP0689459B1/en
Priority to ES94909262T priority patent/ES2183836T3/es
Priority to CZ952426A priority patent/CZ242695A3/cs
Priority to SG1996007056A priority patent/SG73411A1/en
Priority to KR1019950703985A priority patent/KR960700756A/ko
Priority to NZ262484A priority patent/NZ262484A/en
Priority to PCT/GB1994/000558 priority patent/WO1994021300A2/en
Priority to DK94909262T priority patent/DK0689459T3/da
Priority to DE69431832T priority patent/DE69431832T2/de
Priority to CNB941921255A priority patent/CN1195551C/zh
Priority to IL10904594A priority patent/IL109045A0/xx
Priority to IN200MA1994 priority patent/IN178499B/en
Priority to NO953643A priority patent/NO953643L/no
Priority to US11/819,647 priority patent/US20080070278A1/en
Priority to JP2007211720A priority patent/JP4740206B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
GB939305735A 1993-03-19 1993-03-19 Novel agent for controlling cell activity Pending GB9305735D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GB939305735A GB9305735D0 (en) 1993-03-19 1993-03-19 Novel agent for controlling cell activity
CNB941921255A CN1195551C (zh) 1993-03-19 1994-03-18 控制细胞活性的新试剂
ES94909262T ES2183836T3 (es) 1993-03-19 1994-03-18 Nuevo agente para controlar la actividad celular.
SG1996007056A SG73411A1 (en) 1993-03-19 1994-03-18 Novel agent for controlling cell activity
AT94909262T ATE228856T1 (de) 1993-03-19 1994-03-18 Mittel für die steuerung von der zellaktivität
FI954390A FI954390L (fi) 1993-03-19 1994-03-18 Uusi aine solun aktiviteetin säätämiseksi
PT94909262T PT689459E (pt) 1993-03-19 1994-03-18 Novo agente para o controlo da actividade celular
BR9406232A BR9406232A (pt) 1993-03-19 1994-03-18 Novo agente para controle da atividade celular
CA002158647A CA2158647A1 (en) 1993-03-19 1994-03-18 Conjugate containing botulinum toxin translocation and effector domains and heterologocus binding domain for the targeted control of cell activity
HU9502673A HU217220B (hu) 1993-03-19 1994-03-18 Eljárás új sejtaktívitást szabályozó szer előállítására
SK1155-95A SK115595A3 (en) 1993-03-19 1994-03-18 An agent for controlling cell interaction with its external environment and application this agent
JP52080694A JP4300265B2 (ja) 1993-03-19 1994-03-18 細胞活性を制御するための新規作用薬
EP94909262A EP0689459B1 (en) 1993-03-19 1994-03-18 Novel agent for controlling cell activity
PL94310698A PL178895B1 (pl) 1993-03-19 1994-03-18 Nowy oczyszczony czynnik do kontrolowania oddziaływania komórki z jej środowiskiem zewnętrznym i sposób wytwarzania czynnika do kontrolowania oddziaływania komórki z jej środowiskiem zewnętrznym
CZ952426A CZ242695A3 (en) 1993-03-19 1994-03-18 Agent for regulation of a cell interaction with its outer environment, process of its preparation, regulation method of the cell interaction with its outer environment and the use of such agent
AU62175/94A AU671203C (en) 1993-03-19 1994-03-18 Novel agent for controlling cell activity
KR1019950703985A KR960700756A (ko) 1993-03-19 1994-03-18 신규한 세포 활성 조절제(novel agent for controlling gell activity)
NZ262484A NZ262484A (en) 1993-03-19 1994-03-18 An agent for controlling the interaction of a cell with its environment by controlling the transport of intergal membrane proteins (imp)
PCT/GB1994/000558 WO1994021300A2 (en) 1993-03-19 1994-03-18 Novel agent for controlling cell activity
DK94909262T DK0689459T3 (da) 1993-03-19 1994-03-18 Middel til styring af celleaktivitet
DE69431832T DE69431832T2 (de) 1993-03-19 1994-03-18 Mittel für die steuerung von der zellaktivität
IL10904594A IL109045A0 (en) 1993-03-19 1994-03-20 Agent for controlling cell activity and its manufacture
IN200MA1994 IN178499B (enExample) 1993-03-19 1994-03-21
NO953643A NO953643L (no) 1993-03-19 1995-09-15 Nytt middel til kontroll av celleaktivitet
US11/819,647 US20080070278A1 (en) 1993-03-19 2007-06-28 Novel agent for controlling cell activity
JP2007211720A JP4740206B2 (ja) 1993-03-19 2007-08-15 細胞活性を制御するための新規作用薬

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939305735A GB9305735D0 (en) 1993-03-19 1993-03-19 Novel agent for controlling cell activity

Publications (1)

Publication Number Publication Date
GB9305735D0 true GB9305735D0 (en) 1993-05-05

Family

ID=10732382

Family Applications (1)

Application Number Title Priority Date Filing Date
GB939305735A Pending GB9305735D0 (en) 1993-03-19 1993-03-19 Novel agent for controlling cell activity

Country Status (25)

Country Link
US (1) US20080070278A1 (enExample)
EP (1) EP0689459B1 (enExample)
JP (2) JP4300265B2 (enExample)
KR (1) KR960700756A (enExample)
CN (1) CN1195551C (enExample)
AT (1) ATE228856T1 (enExample)
AU (1) AU671203C (enExample)
BR (1) BR9406232A (enExample)
CA (1) CA2158647A1 (enExample)
CZ (1) CZ242695A3 (enExample)
DE (1) DE69431832T2 (enExample)
DK (1) DK0689459T3 (enExample)
ES (1) ES2183836T3 (enExample)
FI (1) FI954390L (enExample)
GB (1) GB9305735D0 (enExample)
HU (1) HU217220B (enExample)
IL (1) IL109045A0 (enExample)
IN (1) IN178499B (enExample)
NO (1) NO953643L (enExample)
NZ (1) NZ262484A (enExample)
PL (1) PL178895B1 (enExample)
PT (1) PT689459E (enExample)
SG (1) SG73411A1 (enExample)
SK (1) SK115595A3 (enExample)
WO (1) WO1994021300A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69511860T2 (de) 1994-05-31 2000-02-10 Allergan, Inc. Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
GB9410871D0 (en) 1994-05-31 1994-07-20 Imperial College Modification of tetanus toxin for use as a transport protein
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
KR100580541B1 (ko) * 1998-05-13 2006-05-16 비오테크콘 게젤샤프트 퓌어 비오테크놀로지셰 엔트리클룽 운트 콘술팅 엠베하 비만세포의 과립소실을 억제하기 위한 혼성 단백질 및 그사용방법
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
EP2267008B1 (en) 1999-08-25 2014-07-02 Allergan, Inc. Activatable recombinant neurotoxins
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
GB9926875D0 (en) * 1999-11-12 2000-01-12 Microbiological Research Agenc Use of lytic toxins and toxin conjugates
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6773711B2 (en) 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6319506B1 (en) 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
GB0216865D0 (en) * 2002-07-19 2002-08-28 Microbiological Res Authority Targetted agents for nerve regeneration
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
SI1531647T1 (sl) * 2003-11-14 2010-04-30 Starhome Gmbh Upravljanje zakljužśenih klicev za gostujožśe narožśnike mobilnih telefonov
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) * 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1861419B1 (en) 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
AU2007347781B2 (en) 2006-07-11 2013-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
JP5728380B2 (ja) 2008-06-12 2015-06-03 シンタクシン リミテッドＳｙｎｔａｘｉｎ Ｌｉｍｉｔｅｄ 神経内分泌疾患の抑制
BRPI0915142A8 (pt) 2008-06-12 2018-01-02 Syntaxin Ltd Polipeptídeos, ácido nucleico e usos dos mesmos
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
GB201219024D0 (en) 2012-10-23 2012-12-05 Syntaxin Ltd Assay
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
WO2019224184A1 (en) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
JP2024513191A (ja) 2021-03-30 2024-03-22 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
EP0329184A3 (en) * 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US5045451A (en) * 1988-10-26 1991-09-03 Board Of Regents Methods for screening antibodies for use as immunotoxins
WO1990010692A1 (en) * 1989-03-15 1990-09-20 University Of Florida Monoclonal antibody for use in detection and treatment of childhood leukemia
US5300496A (en) * 1991-09-30 1994-04-05 The University Of British Columbia Complexed vanadium for the treatment of diabetes mellitus
US5877295A (en) * 1992-09-30 1999-03-02 The Center For Blood Research Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen

Also Published As

Publication number Publication date
PT689459E (pt) 2003-04-30
PL310698A1 (en) 1995-12-27
NO953643D0 (no) 1995-09-15
AU6217594A (en) 1994-10-11
IN178499B (enExample) 1997-05-03
JP2007302696A (ja) 2007-11-22
BR9406232A (pt) 1996-01-09
NO953643L (no) 1995-11-16
CZ242695A3 (en) 1996-04-17
CN1124929A (zh) 1996-06-19
FI954390A0 (fi) 1995-09-18
HUT76556A (en) 1997-09-29
FI954390A7 (fi) 1995-11-17
EP0689459A1 (en) 1996-01-03
HU9502673D0 (en) 1995-11-28
JP4300265B2 (ja) 2009-07-22
US20080070278A1 (en) 2008-03-20
JP4740206B2 (ja) 2011-08-03
AU671203B2 (en) 1996-08-15
DE69431832D1 (de) 2003-01-16
ES2183836T3 (es) 2003-04-01
IL109045A0 (en) 1994-06-24
JPH09500867A (ja) 1997-01-28
CN1195551C (zh) 2005-04-06
HU217220B (hu) 1999-12-28
ATE228856T1 (de) 2002-12-15
DE69431832T2 (de) 2003-04-10
AU671203C (en) 2003-02-27
FI954390L (fi) 1995-11-17
PL178895B1 (pl) 2000-06-30
NZ262484A (en) 1996-08-27
SK115595A3 (en) 1997-02-05
WO1994021300A2 (en) 1994-09-29
KR960700756A (ko) 1996-02-24
DK0689459T3 (da) 2003-03-24
CA2158647A1 (en) 1994-09-29
EP0689459B1 (en) 2002-12-04
SG73411A1 (en) 2000-06-20

Similar Documents

Publication Publication Date Title
SG73411A1 (en) Novel agent for controlling cell activity
ZA963129B (en) A novel agent able to modify peripheral afferent function
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
IL151371A0 (en) Modified porcine factor viii and pharmaceutical compositions containing the same
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
PT1200105E (pt) Factor viii modificado
DE69416824D1 (de) Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen
ATE187651T1 (de) Zweikomponenten-fibrinkleber
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
AU6839898A (en) Vaccine composition for preventing or treating c hepatitis
AU2001232994A1 (en) Compositions treated to inactivate infectious proteins
WO2000069891A3 (en) Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
AU642979B2 (en) Utilization and delivery of enzymes
HK1001036A (en) Novel agent for controlling cell activity
KR910700067A (ko) 항 hiv제
NO960710D0 (no) Nye tripeptider nyttige i immun- og CNS-terapi
ATE171072T1 (de) Rezeptor-konjugate zum targeting von arzneiwirkstoffen und anderen wirksubstanzen
BR9712628A (pt) Derivados de 8(9)-deidroestradiol
WO2004041856A3 (en) Crystal structures of bacterial inorganic pyrophosphatases